BioClinica appoints Andrzej Dzik-Jurasz as its new medical director

BioClinica Appoints Senior Medical Director, Dr. Andrzej Dzik-Jurasz

New Position Expands Scientific Coverage for MRI Imaging and Oncology

NEWTOWN, Pa.–(BUSINESS WIRE)–BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced the appointment of Andrzej (Andy) Dzik-Jurasz, M.D., Ph.D. as Senior Medical Director for Medical Affairs, a newly created position. Dr. Dzik-Jurasz brings more than 15 years of clinical, radiological and pharmaceutical industry experience with major pharmaceutical companies such as Novartis Pharmaceuticals and GlaxoSmithKline.

“He will be responsible for leading our global oncology strategy, including the development and implementation of new offerings to support our clients’ clinical studies. Andy’s expertise in MRI imaging also provides additional depth for our imaging clientele.”
“Dr. Dzik-Jurasz’s appointment to this newly created position will help support BioClinica’s growth initiatives within our imaging core lab solutions business,” said Mark Weinstein, CEO of BioClinica. “He will be responsible for leading our global oncology strategy, including the development and implementation of new offerings to support our clients’ clinical studies. Andy’s expertise in MRI imaging also provides additional depth for our imaging clientele.”

Dr. Dzik-Jurasz is widely published in radiology with more than 40 publications in clinical and research journals. His academic and pharmaceutical industry experience has focused on imaging in clinical drug development. He has participated in all facets of the clinical trial process from Phase I to IV, with particular expertise in the field of oncology.

Dr. Dzik-Jurasz will report to Colin Miller, Ph.D. FICR CSci, Senior Vice President of Medical Affairs, who added, “Andy is a gifted and disciplined researcher who will make an immediate contribution to BioClinica’s culture of excellence and innovation for clinical trial support. His exceptional qualifications as a physician investigator combine an impressive scientific track record with a passion for the use of imaging in drug development. We are extremely pleased to have him join our team.”

Dr. Dzik-Jurasz joins BioClinica from Novartis where he held the position of Executive Director, Global Head Oncology Translational Imaging. Prior to that he was Vice President of Clinical Development for Point Therapeutics; Head of Imaging for Epix Pharmaceuticals, and Senior Director in Translational Medicine and Technology at GlaxoSmithKline. Dr. Dzik-Jurasz received his medical degree from Westminster Medical School, London, UK, and his Ph.D. from the Institute of Cancer Research, London, UK. He is a Fellow of the Royal College of Surgeons of England and Fellow of the Royal College of Radiologists.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Contacts

BioClinica, Inc.
Jim Dorsey, 267-757-3040
or
Diccicco Battista Communications
Trade Media – Rachel Summers
484-342-3600
or
Porter, LeVay & Rose, Inc.
Investor Contact – Michael Porter
Financial Media – Bill Gordon
212-564-4700